REVLON's OTC PAIN RELIEF PRODUCT MITCHUM SOLID RELIEF Pain Relieving Stick, is being introduced this month at mass market outlets. The solid-gel formula will be positioned as a "clean and efficient" alternative to cream analgesic rubs for temporary relief from minor arthritis pain and aching muscles, according to Revlon. A 2 oz. stick will be priced at a suggested $4.99. Solid Relief will be offered in two formulas: "Extra Strength" and "Maximum Strength." Labels on both products will state: "Contains more pain medication than the leading ointment." Revlon said in a press release that both the Extra and Maximum Strengths contain more of the active ingredients methyl salicylate and menthol than the "most popular rubs." Maximum Strength Mitchum Solid Relief contains "more than any product now available," Revlon noted. The "Extra Strength" contains a 30% concentration of methyl salicylate and 13% menthol, while the "Maximum Strength" product contains 35% methyl salicylate and 15% menthol. The solid-gel stick formulas will be advertised as penetrating skin more efficiently than ointments, particularly in "hard-to-reach" areas, Revlon says. The stick form also provides a massaging action, the company noted. Solid Relief is formulated for quick applications; it will not stain skin or clothes and does not leave an oily or waxy residue like cream rubs, according to the company. Since it sold its Norcliff-Thayer unit to Beecham in 1985, Revlon's OTC drug business has been limited to drug/cosmetic type products such as dandruff shampoos and antiperspirants. Those products fit more closely with Revlon's strategic focus on cosmetics and fragrances. The Mitchum analgesic product gives Revlon a chance to see if the "stick" cosmetic technology can cross over into the OTC drug area and gain consumer acceptance as a novel external analgesic product.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
In line with new President Lee’s campaign pledges, South Korea's newly confirmed health minister is expected to tackle key issues including a prolonged doctors' conflict, essential drug supplies and R&D support for the industry.
The removal of CBER Director Prasad comes after a wave of right-wing backlash to his appointment over the past few days that was also critical of his decision to ask Sarepta to suspend all sales of the DMD gene therapy Elevidys. FDA reversed its decision the day before Parsad's departure.
Meanwhile, companies continue discussions with the Trump Administration over ways of increasing what European nations pay for drugs as an alternative to imposing a Most Favored Nation drug pricing policy in the US.
